September 22, 2022
Appointment fortifies Imagia Canexia Health’s board with leading expertise in successfully scaling biopharma and diagnostics enterprises
August 30, 2022
NGS Reporting, Whole Genome Sequencing, and In-House Testing major themes in this year’s meeting
July 21, 2022
In this presentation, Dr. Gregory Tranah, of Sutter Health, discusses opportunities and challenges that bringing in-house testing to a large, complex, health system presents. Dr. Tranah will discuss critical success factors for others who are considering embarking on this path.
June 15, 2022
Health Canada Authorizes Imagia Canexia Health Insights Platform to be Manufactured and Distributed Across Canada
Leveraging the Imagia Canexia Health Insights Platform (ICHIP), now Canadian oncologists can deliver precision cancer treatments to patients no matter where they live.
June 15, 2022
Imagia Canexia Health Achieves First CE-IVD Status in the E.U. to Deploy Comprehensive Cancer Testing Platform
Imagia Canexia Health, a genomics-based cancer treatment testing company that accelerates access to precision care by combining AI expertise with advanced molecular biopsy solutions, today announced the CE-IVD marking for its Imagia Canexia Health Insights Platform (ICHIP) to operate across Europe.
June 3, 2022
This article from BioWorld Medtech includes an interview with our CMO David Huntsman, where he discusses Imagia Canexia Health's Candetect project, which is developing precision oncology software that will help monitor resistance to cancer therapy and treatment relapse in individual cancer survivors.